{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"7.36","value":"1.22"},{"groupId":"OG001","lowerLimit":"0.92","upperLimit":"6.74","value":"1.92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"TTR was defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that was subsequently confirmed.","dispersionType":"Full Range","groups":[{"description":"BCMA-naïve participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Cohort A"},{"description":"BCMA-exposed participants received subcutaneous elranatamab with a priming regimen of 12 milligrams (mg) on Cycle 1 Day 1 and 32 mg on Cycle 1 Day 4 followed by 76 mg weekly thereafter starting from Cycle 1 Day 8.","id":"OG001","title":"Cohort B"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set in each cohort included all enrolled participants in the respective cohort who received at least one dose of study intervention. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)","title":"Time-to-Response (TTR) as Per IMWG Criteria by BICR","type":"SECONDARY","unitOfMeasure":"Months"}